List of Excipients in Branded Drug FENOPROFEN CALCIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	BROWN IRON OXIDE
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	CROSPOVIDONE
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	GELATIN
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	MAGNESIUM STEARATE
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	SODIUM LAURYL SULFATE
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	TALC
Misemer Pharmaceuticals Inc	FENOPROFEN CALCIUM	fenoprofen calcium	0276-0503	TITANIUM DIOXIDE

Generic Drugs Containing FENOPROFEN CALCIUM

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	AMMONIA
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	CROSPOVIDONE
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C BLUE NO. 1
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C RED NO. 40
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C YELLOW NO. 6
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FERRIC OXIDE YELLOW
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	GELATIN

What are the Most Frequently-Used Excipients in FENOPROFEN CALCIUM?

# Of NDCs	Excipient
1	AMMONIA
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
4	CROSPOVIDONE
4	FD&C BLUE NO. 1
4	FD&C RED NO. 40
5	FD&C YELLOW NO. 6

Fenoprofen Calcium Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Fenoprofen calcium is a legacy nonsteroidal anti-inflammatory drug with limited current commercial momentum, no meaningful modern exclusivity barrier, and a formulation profile suited to low-cost immediate-release products. The strongest opportunities are not new-molecule exclusivity plays. They are differentiated generic formulations, supply-chain optimization, niche dosage forms, and regional products where fenoprofen remains approved or commercially recognized.

The core excipient strategy should prioritize rapid dissolution, capsule-fill uniformity, moisture control, low manufacturing cost, and avoidance of unnecessary formulation complexity. The principal commercial risks are weak market demand, competition from inexpensive NSAIDs, limited clinical differentiation, and the absence of a strong patent-based pricing position.

What is fenoprofen calcium and how is it currently formulated?

Fenoprofen calcium is the calcium salt of fenoprofen, an NSAID indicated for symptomatic treatment of rheumatoid arthritis and osteoarthritis. The reference product, Nalfon, was marketed in oral capsule strengths including 200 mg and 300 mg. Fenoprofen calcium is administered as an immediate-release oral product rather than as a modified-release or enteric-coated product in the principal U.S. labeling.

Fenoprofen is a relatively old NSAID. The FDA approved Nalfon in the 1970s, placing its original regulatory exclusivity and early patent position well outside the current commercial period. The present opportunity is therefore primarily generic and formulation-based rather than compound-based.

Attribute	Fenoprofen calcium
Therapeutic class	NSAID
Common use	Osteoarthritis and rheumatoid arthritis
Dosage form	Immediate-release oral capsules
Historical U.S. brand	Nalfon
Common strengths	200 mg and 300 mg capsules
Salt form	Calcium salt
Regulatory status	Legacy FDA-approved drug; generic pathway available
Main formulation issue	Consistent dissolution and capsule-fill performance
Primary commercial constraint	Low differentiation versus other NSAIDs

The Nalfon label identifies conventional excipients used in hard gelatin capsules, including lactose monohydrate, povidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, titanium dioxide, gelatin, and colorants. Exact composition can vary by manufacturer and strength, so a generic sponsor must rely on the current product-specific labeling and its own approved manufacturing dossier rather than assume that all fenoprofen calcium products use the same formulation.[1]

What excipients are used in fenoprofen calcium capsules?

The reference formulation uses a conventional direct-compression or granulation-oriented excipient system designed for an immediate-release capsule. The main functional categories are:

Excipient category	Examples reported in product labeling	Primary function
Diluent	Lactose monohydrate	Provides capsule-fill mass and improves powder handling
Binder	Povidone	Supports granule or blend cohesion
Disintegrant	Croscarmellose sodium	Promotes rapid capsule-plug breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces adhesion and ejection force
Wetting aid	Sodium lauryl sulfate	Improves wetting of hydrophobic drug particles
Capsule shell	Gelatin, titanium dioxide, colorants	Provides dosage-form structure and product identification

Fenoprofen calcium has a relatively high active load in a 200 mg or 300 mg capsule. The formulation is therefore sensitive to powder density, particle-size distribution, electrostatic behavior, and segregation. A sponsor replacing lactose, sodium lauryl sulfate, or gelatin should evaluate not only dissolution but also blend uniformity, capsule fill weight, shell compatibility, stability, and manufacturing throughput.

What is the role of lactose in fenoprofen calcium products?

Lactose monohydrate is a cost-efficient filler that supports capsule mass and improves powder compaction. It can be suitable where the drug substance has poor bulk density or poor flow. The main commercial limitations are lactose intolerance labeling concerns, potential interaction with amine-containing compounds in other formulations, and supplier variability in particle-size distribution.

For fenoprofen calcium, lactose can remain an effective low-cost choice where the target market accepts animal-derived or dairy-derived excipients. A lactose-free formulation may have greater positioning value in institutional, specialty-pharmacy, or export markets than in a conventional U.S. generic market.

Why is sodium lauryl sulfate relevant?

Sodium lauryl sulfate can improve wetting of hydrophobic drug particles and reduce variability in dissolution. It can also create processing and tolerability concerns if used at an unnecessarily high level. A sponsor may test lower concentrations, poloxamers, sodium docusate, or surfactant-free particle-engineering approaches.

The commercial objective should be the lowest concentration that produces reliable dissolution across clinically relevant pH conditions. Removing the surfactant can simplify labeling and reduce excipient objections, but the change requires comparative dissolution and bioequivalence support.

What capsule-shell options are available?

A conventional hard gelatin shell is the lowest-cost option and is consistent with the legacy dosage form. Hypromellose capsules can support vegetarian, halal, kosher, or gelatin-free positioning. They may also reduce sensitivity to certain humidity conditions, although the impact depends on the shell supplier, packaging system, and storage environment.

A shell conversion is commercially meaningful only if it supports a defined market strategy. It is unlikely to create substantial pricing power in a standard U.S. generic tender. It may be more useful in private-label, international, or pharmacy-channel products with specific consumer or institutional requirements.

What is the best excipient strategy for a new fenoprofen calcium generic?

The most defensible strategy is a simple immediate-release capsule with robust dissolution and a short, reliable supply chain.

Strategy 1: Reference-like, low-cost formulation

A reference-like formulation would retain lactose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and a conventional capsule shell. This approach reduces technical risk and supports a conventional abbreviated new drug application pathway.

Its advantages are:

• Familiar manufacturing process
• Low excipient cost
• Straightforward capsule filling
• Established functional roles
• Limited need for novel formulation justification

Its disadvantages are limited differentiation and possible dependence on a narrow supplier base for colored capsules or specific excipient grades.

Strategy 2: Lactose-free formulation

A lactose-free product could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. The choice depends on bulk density, flow, compressibility, moisture behavior, and capsule-fill volume.

Microcrystalline cellulose may improve compaction and provide a familiar regulatory profile. Mannitol can support a cleaner sensory and labeling position but may increase cost. Dibasic calcium phosphate can improve density but may alter dissolution and is less attractive where calcium loading or mineral-related labeling is a concern.

The principal risk is that a replacement filler changes the drug-excipient microenvironment and requires renewed optimization of disintegration and dissolution.

Strategy 3: Gelatin-free capsule

A hypromellose capsule can support vegetarian and religious-diet claims. This is a moderate-differentiation strategy rather than a strong clinical strategy. It may be attractive for export markets and online pharmacy channels but usually will not justify a large price premium in generic procurement.

Strategy 4: Low-moisture, high-stability formulation

Fenoprofen calcium products should be evaluated for moisture sensitivity, particularly where the formulation uses hygroscopic excipients or a high-surface-area drug substance. A low-moisture process, controlled-humidity blending, and high-barrier packaging may provide more commercial value than adding a complex excipient system.

Potential packaging options include:

• Aluminum-aluminum blister packs
• High-density polyethylene bottles with desiccant
• Induction-sealed bottles
• Moisture-barrier unit-dose packaging

Packaging is not an excipient, but it can determine whether a low-cost formulation maintains dissolution and appearance through shelf life.

What formulation patents protect fenoprofen calcium products?

The original compound and early product protection for fenoprofen are expired. A modern sponsor should not expect meaningful market protection from the historical Nalfon intellectual-property position.

Current patent value, if any, would more likely arise from:

• A novel controlled-release system
• A specific multiparticulate or pellet architecture
• A taste-masked liquid formulation
• A co-processed excipient system
• A new dosage form or administration route
• A manufacturing process with measurable performance advantages
• A fixed-dose combination
• A method of use involving a new patient population or dosing regimen

A routine substitution of lactose with microcrystalline cellulose, conversion from gelatin to hypromellose, or use of a conventional disintegrant would usually be difficult to protect broadly unless the formulation produces an unexpected technical result.

Potential IP category	Commercial relevance	Likely strength
Original fenoprofen compound	Historical only	Expired
Conventional immediate-release capsule	Generic entry basis	Low
Alternative filler or lubricant	Limited	Low
Gelatin-free shell	Moderate market positioning	Low to moderate
Novel extended-release system	Potentially meaningful	Depends on claims and data
Pediatric liquid or dispersible product	Potential niche	Depends on approval and clinical need
Manufacturing process	Possible defensive value	Narrow
Fixed-dose combination	Potentially higher	Depends on clinical and regulatory support

No meaningful Orange Book strategy should be assumed for a conventional fenoprofen calcium capsule without a current product-specific review of FDA listings and approved labeling. The commercial case should be based on generic approval, manufacturing economics, and market access rather than expected patent exclusivity.

When does fenoprofen calcium lose exclusivity?

Fenoprofen calcium lost its original market exclusivity decades ago. The key commercial question is not the expiration of a current patent but whether a sponsor can obtain approval and secure sufficient demand in a low-price generic market.

Exclusivity element	Fenoprofen calcium position
Original small-molecule exclusivity	Expired
Historical compound patents	Expired
Modern NCE exclusivity	Not applicable
Pediatric exclusivity	No current strategic significance identified
Orphan exclusivity	Not applicable to the established indications
Generic pathway	Available in principle under an ANDA
Biosimilar pathway	Not applicable
Current commercial barrier	Market size, reimbursement, supply economics

A conventional generic applicant would generally pursue an ANDA referencing the listed reference drug, subject to current FDA product-specific requirements. Bioequivalence, chemistry-manufacturing-controls data, labeling, facility compliance, and any applicable therapeutic-equivalence requirements remain central to approval.[2]

What is the Orange Book status of fenoprofen calcium?

The Orange Book is the principal FDA source for approved drug products, therapeutic-equivalence evaluations, patent listings, and exclusivity information. Fenoprofen calcium should be assessed through the current Orange Book and Drugs@FDA records because listed strengths, marketing status, reference-product designations, and patent information can change over time.[2,3]

For commercial planning, the relevant questions are:

1. Which fenoprofen calcium product is the current reference listed drug?
2. Which strengths have active or withdrawn marketing status?
3. Are any patents or regulatory exclusivities listed?
4. Does the proposed dosage form match the reference product?
5. Are there product-specific bioequivalence recommendations?
6. Are there supply or discontinuation issues affecting the reference product?

A sponsor should treat a discontinued or supply-constrained reference product as a potential regulatory and commercial complication, not automatically as an opportunity. FDA approval does not guarantee a viable market if wholesalers, payers, and pharmacies do not maintain demand.

Are Paragraph IV challenges relevant to fenoprofen calcium?

Paragraph IV litigation is unlikely to be a central issue for a conventional fenoprofen calcium generic because the original product protections are historical and the product is not a major branded revenue asset.

A Paragraph IV certification could still become relevant if a current sponsor obtains a patent on a new formulation, delivery system, method of use, or manufacturing process. In that case, an ANDA applicant could challenge the listed patent, and the patent holder could trigger the statutory 30-month stay by filing suit within the applicable period under the Hatch-Waxman framework.[4]

The practical risk profile is therefore:

Scenario	Paragraph IV risk
Conventional capsule matching legacy product	Low
Lactose-free capsule with routine excipients	Low
Gelatin-free shell	Low
New controlled-release formulation	Moderate to high
Fixed-dose combination	Moderate
New method-of-use claim	Moderate
Novel process patent	Product- and claim-specific

What generic entry risks exist for fenoprofen calcium?

The primary risk is commercial erosion from competing NSAIDs rather than patent blockage. Fenoprofen competes with ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, indomethacin, and other anti-inflammatory therapies. Many competitors have broader distribution, higher prescribing familiarity, or lower unit cost.

Clinical and market risks

Fenoprofen has no obvious current differentiation in the standard oral NSAID market. It carries class-level NSAID risks, including gastrointestinal bleeding, cardiovascular events, renal toxicity, hypertension, and drug interactions. The FDA class labeling and boxed-warning framework apply to the relevant risks of NSAID therapy.[5]

Manufacturing risks

The principal technical risks include:

• Poor flow of the active-excipient blend
• Segregation during capsule filling
• Inconsistent dissolution caused by particle-size variation
• Over-lubrication from magnesium stearate
• Moisture-related stability changes
• Capsule-shell brittleness or cross-linking
• Supplier discontinuation for colors or specialty grades

Market-access risks

A sponsor may face:

• Low or intermittent wholesaler demand
• Limited formulary preference
• High price compression
• Minimum-order requirements
• Difficulty achieving commercial scale
• Competition from therapeutically substitutable NSAIDs
• Low physician familiarity relative to newer products

What commercial opportunities exist for fenoprofen calcium?

The strongest opportunities are narrow and execution-dependent.

Contract and private-label manufacturing

A manufacturer with existing capsule equipment can add fenoprofen calcium with limited process investment. The opportunity is strongest where the manufacturer already handles NSAIDs, has validated capsule-filling capacity, and can purchase active ingredient in economical volumes.

Regional generic supply

Some markets may maintain demand for legacy NSAIDs through hospital tenders, government procurement, or established physician prescribing. Regional registration can be commercially attractive where the product is already recognized and competition is limited.

The key variables are local approval status, API registration, reference-product requirements, pharmacopoeial standards, and tender pricing.

Gelatin-free and lactose-free products

These formulations can create modest differentiation in pharmacy and export channels. Their value is greater when linked to a documented procurement requirement or consumer preference. They are less likely to produce durable pricing power in U.S. generic reimbursement.

Liquid or dispersible dosage forms

A liquid suspension, powder for suspension, or dispersible tablet could address swallowing difficulty. Fenoprofen calcium’s established adult use and the absence of a broad pediatric indication limit the size of this opportunity. Any new dosage form would require formulation, stability, dose-uniformity, microbial, and bioequivalence or clinical justification appropriate to the proposed product.

Fixed-dose combinations

A combination with a gastroprotective agent or another analgesic could offer differentiation, but it would require a strong clinical rationale, careful safety analysis, and a more complex regulatory program. The commercial risk would be substantially higher than for a conventional generic capsule.

Excipient and packaging supply

A smaller opportunity exists for suppliers of:

• Low-substituted croscarmellose sodium
• Direct-flow lactose
• Co-processed fillers
• Hypromellose capsules
• Moisture-barrier bottles and blisters
• Low-peroxide povidone
• Pharmaceutical-grade surfactants

The supply opportunity depends on annual volume. Fenoprofen calcium alone is unlikely to support a major dedicated excipient platform, but it can fit within a broader NSAID portfolio.

How does fenoprofen calcium compare with competing NSAIDs?

Fenoprofen calcium is commercially weaker than leading generic NSAIDs because it lacks a clear current advantage in convenience, dosing frequency, safety, or cost.

Product	Commercial position	Formulation opportunity	Competitive pressure
Fenoprofen calcium	Legacy NSAID	Simple capsule, niche reformulation	High
Ibuprofen	Broad OTC and prescription presence	Liquids, softgels, tablets	Very high
Naproxen	Strong OTC and prescription presence	Delayed-release and suspensions	Very high
Diclofenac	Multiple dosage forms and indications	Topical, oral, ophthalmic	Very high
Meloxicam	Prescription chronic-use positioning	Tablets, oral suspension	High
Celecoxib	COX-2 positioning	Capsules and branded differentiation	High

Fenoprofen may still have value as a portfolio-completion product for a manufacturer that already sells multiple prescription NSAIDs. It is less attractive as a stand-alone investment requiring new facilities, substantial clinical development, or a premium brand strategy.

What regulatory status applies to new fenoprofen calcium formulations?

A conventional generic capsule would generally be evaluated through the ANDA pathway if it references an approved U.S. product and meets applicable sameness and bioequivalence requirements. A materially different dosage form, strength, route, or formulation may require a different FDA pathway or additional clinical evidence.

A sponsor should establish:

• Active moiety and salt-form requirements
• Reference listed drug and strength mapping
• Product-specific bioequivalence recommendations
• Dissolution method and acceptance criteria
• Drug-substance particle-size controls
• Impurity and degradation specifications
• Capsule-shell compatibility
• Stability under ICH conditions
• Labeling alignment
• Facilities and supplier qualification

The FDA Inactive Ingredient Database can support excipient precedent analysis, but database presence does not replace product-specific safety, quality, and regulatory evaluation.[6]

How strong is the fenoprofen calcium patent estate?

The patent estate is weak for conventional products. Historical protection has expired, and routine excipient substitutions are unlikely to create broad exclusivity.

A stronger asset would require measurable technical differentiation, such as:

• A clinically useful reduction in dosing frequency
• Improved gastrointestinal tolerability supported by clinical data
• Reliable absorption despite food effects
• A stable liquid or pediatric-compatible dosage form
• A novel multiparticulate system
• A protected manufacturing process that materially lowers cost

Even a granted formulation patent would need to be evaluated against claim breadth, enablement, obviousness, freedom to operate, Paragraph IV exposure, and the limited revenue potential of the underlying drug.

What revenue exposure and launch scenarios apply?

Fenoprofen calcium should be modeled as a low-to-moderate revenue generic unless a sponsor has verified institutional demand or a supply shortage.

Launch scenario	Revenue profile	Investment case
Standard 200 mg and 300 mg capsules	Low	Requires very low manufacturing cost
Single-strength launch	Low	Limits inventory and regulatory cost
Lactose-free or gelatin-free variant	Low to moderate	Depends on channel-specific demand
Regional tender product	Moderate if awarded	Volume-driven, price-sensitive
Novel extended-release product	Uncertain	Higher development and patent cost
Fixed-dose combination	Uncertain	Higher regulatory and clinical risk
Private-label portfolio addition	Incremental	Attractive with existing infrastructure

A staged launch is commercially rational: begin with the highest-demand strength, use a validated conventional excipient system, and avoid expensive differentiation unless market evidence supports it. The product should be evaluated as part of a broader NSAID portfolio rather than as a stand-alone premium opportunity.

Key Takeaways

• Fenoprofen calcium is a legacy NSAID with expired original exclusivity and limited patent-based protection.
• The most practical product is a conventional immediate-release capsule using established excipients.
• Lactose-free and gelatin-free versions offer modest differentiation but limited standalone pricing power.
• Dissolution, blend uniformity, moisture control, and capsule-fill performance are the main formulation priorities.
• Paragraph IV risk is low for a standard generic capsule and rises only with new formulation or method-of-use patents.
• The largest commercial risks are weak demand, low reimbursement, and competition from better-known NSAIDs.
• Regional tenders, private-label supply, and portfolio manufacturing are more credible opportunities than a premium branded launch.
• A novel liquid, dispersible, extended-release, or fixed-dose product could create differentiation but would require higher regulatory and clinical investment.

FAQs

Can fenoprofen calcium be reformulated as an oral suspension?

Yes, but an oral suspension would require development of physical stability, redispersibility, dose uniformity, microbial control, preservative performance, and appropriate bioequivalence or clinical support. The commercial opportunity is likely niche because established pediatric demand is limited.

Is fenoprofen calcium suitable for an OTC product?

Potentially, but OTC conversion would require an FDA monograph or approved application pathway, acceptable labeling, dosing, safety data, and a compelling benefit-risk case. The competitive position would be weak against widely available OTC ibuprofen and naproxen.

Which excipient is most important for fenoprofen calcium dissolution?

The most influential variables are usually the drug-substance particle size, wetting system, disintegrant level, lubricant exposure, and granulation or blending process. Sodium lauryl sulfate may improve wetting, while croscarmellose sodium supports rapid breakup.

Could a hypromellose capsule support patent protection?

A hypromellose shell alone is unlikely to support commercially meaningful broad patent protection. Patentability would depend on a novel combination, unexpected stability or dissolution result, or a defined technical advantage supported by data.

Is fenoprofen calcium a viable target for biosimilar development?

No. Fenoprofen calcium is a chemically synthesized small-molecule drug, not a biologic. A biosimilar pathway is not applicable. The relevant route is conventional generic-drug development, normally through an ANDA where the regulatory requirements are satisfied.

References

1. DailyMed. (n.d.). Nalfon- fenoprofen calcium capsule: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
5. U.S. Food and Drug Administration. (2015). FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs increase chance of heart attack or stroke. https://www.fda.gov
6. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/